Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Milestone revenue related to the development of an AI-equipped hemodialysis medical device was recognized, while business expenses including research and development expenses were also recognized.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥10 million (YoY 0.0%) |
| Operating profit | ¥-161 million |
| Ordinary income | ¥-154 million |
| Profit attributable to owners of the parent | ¥-154 million |
| Net income per share | -¥11.25 |
| Equity ratio | End of the current fiscal period 96.7 / End of previous period 94.5 |
| Total assets | ¥3,261 million |
| Net assets | ¥3,167 million |
| Cash flows from operating activities | ¥-208,557 thousand |
| Cash flows from investing activities | ¥-524 thousand |
| Cash flows from financing activities | ¥0 thousand |
| Cash and cash equivalents at end of period | ¥3,193,623 thousand |
| Full-year earnings forecast | Net Sales ¥43 million (YoY -36.4%) / Operating profit ¥-585 million / Ordinary income ¥-547 million / Net income ¥-548 million |
| Annual Dividend Forecast | ¥0.00 → ¥0.00（0.0%） |
| Depreciation and amortization | ¥54 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 13,776,900 shares |
| Treasury Shares at Period-End | 10 shares |
| Factors Behind Changes in Business Performance | Milestone revenue related to the development of an AI-equipped hemodialysis medical device was recognized, while business expenses including research and development expenses were also recognized. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Milestone revenue related to the development of an AI-equipped hemodialysis medical device was recognized. The operating loss was attributed to the recognition of ¥169.823 million in business expenses, including ¥76.282 million in research and development expenses related to treatments for chronic myeloid leukemia and other conditions.